Logo image of APLS

APELLIS PHARMACEUTICALS INC (APLS) Stock Fundamental Analysis

NASDAQ:APLS - Nasdaq - US03753U1060 - Common Stock - Currency: USD

17.69  -0.07 (-0.39%)

After market: 17.69 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to APLS. APLS was compared to 558 industry peers in the Biotechnology industry. APLS may be in some trouble as it scores bad on both profitability and health. APLS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year APLS has reported negative net income.
In the past year APLS has reported a negative cash flow from operations.
In the past 5 years APLS always reported negative net income.
APLS had a negative operating cash flow in each of the past 5 years.
APLS Yearly Net Income VS EBIT VS OCF VS FCFAPLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

Looking at the Return On Assets, with a value of -27.71%, APLS is in the better half of the industry, outperforming 70.20% of the companies in the same industry.
The Return On Equity of APLS (-136.21%) is worse than 61.04% of its industry peers.
Industry RankSector Rank
ROA -27.71%
ROE -136.21%
ROIC N/A
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
APLS Yearly ROA, ROE, ROICAPLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

APLS's Gross Margin of 83.00% is amongst the best of the industry. APLS outperforms 87.07% of its industry peers.
APLS's Gross Margin has declined in the last couple of years.
APLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
APLS Yearly Profit, Operating, Gross MarginsAPLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

APLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APLS has been increased compared to 1 year ago.
Compared to 5 years ago, APLS has more shares outstanding
The debt/assets ratio for APLS has been reduced compared to a year ago.
APLS Yearly Shares OutstandingAPLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
APLS Yearly Total Debt VS Total AssetsAPLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -2.33, we must say that APLS is in the distress zone and has some risk of bankruptcy.
APLS has a Altman-Z score (-2.33) which is in line with its industry peers.
APLS has a Debt/Equity ratio of 2.76. This is a high value indicating a heavy dependency on external financing.
APLS has a Debt to Equity ratio of 2.76. This is amonst the worse of the industry: APLS underperforms 82.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.76
Debt/FCF N/A
Altman-Z -2.33
ROIC/WACCN/A
WACC8.43%
APLS Yearly LT Debt VS Equity VS FCFAPLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

2.3 Liquidity

APLS has a Current Ratio of 4.08. This indicates that APLS is financially healthy and has no problem in meeting its short term obligations.
APLS has a Current ratio (4.08) which is in line with its industry peers.
A Quick Ratio of 3.62 indicates that APLS has no problem at all paying its short term obligations.
APLS's Quick ratio of 3.62 is in line compared to the rest of the industry. APLS outperforms 43.45% of its industry peers.
Industry RankSector Rank
Current Ratio 4.08
Quick Ratio 3.62
APLS Yearly Current Assets VS Current LiabilitesAPLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

APLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.01%, which is quite impressive.
The Revenue has grown by 48.03% in the past year. This is a very strong growth!
The Revenue has been growing by 127.23% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)47.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.19%
Revenue 1Y (TTM)48.03%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%-3.21%

3.2 Future

APLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.31% yearly.
Based on estimates for the next years, APLS will show a quite strong growth in Revenue. The Revenue will grow by 16.01% on average per year.
EPS Next Y-37.39%
EPS Next 2Y24.13%
EPS Next 3Y36.71%
EPS Next 5Y31.31%
Revenue Next Year0.89%
Revenue Next 2Y11.01%
Revenue Next 3Y14.91%
Revenue Next 5Y16.01%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
APLS Yearly Revenue VS EstimatesAPLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
APLS Yearly EPS VS EstimatesAPLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APLS Price Earnings VS Forward Price EarningsAPLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APLS Per share dataAPLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

APLS's earnings are expected to grow with 36.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.13%
EPS Next 3Y36.71%

More info and screens

0

5. Dividend

5.1 Amount

APLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APELLIS PHARMACEUTICALS INC

NASDAQ:APLS (6/20/2025, 8:15:27 PM)

After market: 17.69 0 (0%)

17.69

-0.07 (-0.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners102.48%
Inst Owner Change0.57%
Ins Owners3.77%
Ins Owner Change1.52%
Market Cap2.22B
Analysts78.62
Price Target36.08 (103.96%)
Short Float %23.48%
Short Ratio9.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-37.55%
Min EPS beat(2)-101.36%
Max EPS beat(2)26.26%
EPS beat(4)2
Avg EPS beat(4)-27.55%
Min EPS beat(4)-101.36%
Max EPS beat(4)26.26%
EPS beat(8)4
Avg EPS beat(8)-14.05%
EPS beat(12)5
Avg EPS beat(12)-11.13%
EPS beat(16)5
Avg EPS beat(16)-14.48%
Revenue beat(2)1
Avg Revenue beat(2)-5.68%
Min Revenue beat(2)-16.4%
Max Revenue beat(2)5.05%
Revenue beat(4)2
Avg Revenue beat(4)-3.15%
Min Revenue beat(4)-16.4%
Max Revenue beat(4)5.05%
Revenue beat(8)5
Avg Revenue beat(8)4.07%
Revenue beat(12)7
Avg Revenue beat(12)7.23%
Revenue beat(16)10
Avg Revenue beat(16)41.69%
PT rev (1m)-15.79%
PT rev (3m)-19.16%
EPS NQ rev (1m)-1.83%
EPS NQ rev (3m)-83.97%
EPS NY rev (1m)-2.57%
EPS NY rev (3m)-100.85%
Revenue NQ rev (1m)-0.52%
Revenue NQ rev (3m)-11.49%
Revenue NY rev (1m)-0.52%
Revenue NY rev (3m)-10.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.87
P/FCF N/A
P/OCF N/A
P/B 13.54
P/tB 13.54
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS6.17
BVpS1.31
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.71%
ROE -136.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83%
FCFM N/A
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
F-Score4
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 2.76
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.56%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.08
Quick Ratio 3.62
Altman-Z -2.33
F-Score4
WACC8.43%
ROIC/WACCN/A
Cap/Depr(3y)54.61%
Cap/Depr(5y)218.08%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.19%
EPS Next Y-37.39%
EPS Next 2Y24.13%
EPS Next 3Y36.71%
EPS Next 5Y31.31%
Revenue 1Y (TTM)48.03%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%-3.21%
Revenue Next Year0.89%
Revenue Next 2Y11.01%
Revenue Next 3Y14.91%
Revenue Next 5Y16.01%
EBIT growth 1Y53.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.6%
EBIT Next 3Y47.79%
EBIT Next 5Y41.5%
FCF growth 1Y98.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y98.57%
OCF growth 3YN/A
OCF growth 5YN/A